Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.
Richardson PG, Trudel S, Popat R, Mateos MV, Vangsted AJ, Ramasamy K, Martinez-Lopez J, Quach H, Orlowski RZ, Arnao M, Lonial S, Karanes C, Pawlyn C, Kim K, Oriol A, Berdeja JG, Rodríguez Otero P, Casas-Avilés I, Spirli A, Poon J, Li S, Gong J, Wong L, Lamba M, Pierce DW, Amatangelo M, Peluso T, Maciag P, Katz J, Pourdehnad M, Bahlis NJ; CC-92480-MM-001 Study Investigators. Richardson PG, et al. Among authors: amatangelo m. N Engl J Med. 2023 Sep 14;389(11):1009-1022. doi: 10.1056/NEJMoa2303194. Epub 2023 Aug 30. N Engl J Med. 2023. PMID: 37646702 Clinical Trial.
Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma.
Van Oekelen O, Amatangelo M, Guo M, Upadhyaya B, Cribbs AP, Kelly G, Patel M, Kim-Schulze S, Flynt E, Lagana A, Gooding S, Merad M, Jagganath S, Pierceall WE, Oppermann U, Thakurta A, Parekh S. Van Oekelen O, et al. Among authors: amatangelo m. Cell Rep Med. 2024 May 17:101584. doi: 10.1016/j.xcrm.2024.101584. Online ahead of print. Cell Rep Med. 2024. PMID: 38776911 Free article.
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial.
Lonial S, Popat R, Hulin C, Jagannath S, Oriol A, Richardson PG, Facon T, Weisel K, Larsen JT, Minnema MC, Abdallah AO, Badros AZ, Knop S, Stadtmauer EA, Cheng Y, Amatangelo M, Chen M, Nguyen TV, Amin A, Peluso T, van de Donk NWCJ. Lonial S, et al. Among authors: amatangelo m. Lancet Haematol. 2022 Nov;9(11):e822-e832. doi: 10.1016/S2352-3026(22)00290-3. Epub 2022 Oct 6. Lancet Haematol. 2022. PMID: 36209764 Clinical Trial.
Cultural Perspectives on Pain Assessment and Opioid Use: International Neuroscience Nursing Research Symposium Conference Proceedings.
Bautista C, Amatangelo MP, Baby P, Cassier-Woidasky AK, Dycus K, Edoh EI, Green T, Ilano KCS, Kemboi M, Littlejohns L, Martinez RCKP, Mastamet G, Perera A, Ramazanu S, Ribeiro RM, Serondo DJF, Sila F, Strayer A, Soriano GP, Wessol JL. Bautista C, et al. Among authors: amatangelo mp. J Neurosci Nurs. 2021 Jun 1;53(3):149-156. doi: 10.1097/JNN.0000000000000585. J Neurosci Nurs. 2021. PMID: 33935264
Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma.
Pierceall WE, Amatangelo MD, Bahlis NJ, Siegel DS, Rahman A, Van Oekelen O, Neri P, Young M, Chung W, Serbina N, Parekh S, Agarwal A, Thakurta A. Pierceall WE, et al. Among authors: amatangelo md. Clin Cancer Res. 2020 Nov 15;26(22):5895-5902. doi: 10.1158/1078-0432.CCR-20-1781. Epub 2020 Sep 14. Clin Cancer Res. 2020. PMID: 32928795
ICU Nursing Care of the Stroke Patient.
Amatangelo MP. Amatangelo MP. Crit Care Nurs Clin North Am. 2020 Mar;32(1):ix-x. doi: 10.1016/j.cnc.2019.12.001. Crit Care Nurs Clin North Am. 2020. PMID: 32014165 No abstract available.
Priority Nursing Interventions Caring for the Stroke Patient.
Amatangelo MP, Thomas SB. Amatangelo MP, et al. Crit Care Nurs Clin North Am. 2020 Mar;32(1):67-84. doi: 10.1016/j.cnc.2019.11.005. Epub 2019 Dec 18. Crit Care Nurs Clin North Am. 2020. PMID: 32014162 Review.
32 results